Benefits of Spravato for Treatment-Resistant Depression

Treatment-resistant depression (TRD) is a form of major depressive disorder that does not respond to at least two different antidepressants at adequate doses and durations. Spravato is an FDA-approved nasal spray for adults with TRD, administered under medical supervision in certified treatment centers. It offers an alternative option for individuals who have not improved with standard antidepressant therapies.

What Is Treatment-Resistant Depression?

Treatment-resistant depression is defined as major depressive disorder that does not improve after different antidepressants are taken at adequate doses and durations. Individuals may continue to experience symptoms despite these trials. Causes of TRD can involve genetic, biological, and environmental factors, and assessment relies on a thorough review of treatment history and current symptoms to confirm the diagnosis.

For those who meet the criteria for TRD, alternative options beyond standard antidepressants may be explored. Recognizing treatment-resistant depression involves ongoing assessment by a healthcare provider over time. A thorough history of medication trials and close monitoring of side effects is needed to determine if a patient meets criteria for TRD.

What Are the Symptoms?

Symptoms of treatment-resistant depression persist despite adequate use of at least two different antidepressants. These ongoing symptoms can disrupt personal relationships, work, and daily functioning. Notable symptoms include:

• Persistent Sadness or Emptiness: A low mood that remains constant throughout the day and does not lift in response to positive external events.
• Sleep Disturbances: This includes severe insomnia or hypersomnia (excessive sleeping).
• Cognitive Impairment: Patients often describe “brain fog,” or difficulty concentrating.
• Physical Fatigue: A profound lack of energy where even small tasks require substantial effort.
• Anhedonia: The inability to feel pleasure or interest in activities that were once enjoyable.
• Changes in Appetite: Significant weight loss or weight gain unrelated to dieting.

How Does Spravato Treat It?

Spravato is a nasal spray for adults with treatment-resistant depression, sometimes used alongside an oral antidepressant. It is administered at certified treatment centers under supervision, with patients observed after each dose for potential side effects. Its use is limited to adults who have not responded to at least two other antidepressants.

Treatment with Spravato takes place at certified treatment centers to prioritize patient safety and oversight. The medication is self-administered as a nasal spray under the direct supervision of trained healthcare professionals. After administration, patients remain on site for a minimum observation period, allowing staff to monitor for side effects such as elevated blood pressure, dissociation, or sedation.

Due to the specialized nature of this medication and its effects, ongoing evaluation by medical staff is required throughout the course of treatment. Licensed healthcare providers, including psychiatrists and advanced practitioners, assess each patient’s medical and psychiatric profile before recommending Spravato. Patients can continue taking their oral antidepressant throughout the course of Spravato therapy.

Speak Further With a Psychiatrist

A psychiatrist assesses if Spravato is suitable by reviewing medical history, current symptoms, and safety needs. All treatment is provided under supervision at certified centers in accordance with REMS guidelines. Speak with a psychiatrist to learn more about options for treatment-resistant depression.